CureWorks Collaborative launches to accelerate development of immunotherapy treatments
Share

SEATTLE – June 12, 2018 – Seattle Children’s, with participating members Children’s National Health System, BC Children’s Hospital and Children’s Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children’s hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer. CureWorks focuses on expanding immunotherapy trials and patient access around the world, as well as sharing data and collective expertise to advance novel cell therapies.

CureWorks

CureWorks was founded on the idea that in order to revolutionize treatment for pediatric cancer, academic institutions must work together to achieve better treatments and outcomes for children. As the founding member, Seattle Children’s is seeing promising results in its chimeric antigen receptor (CAR) T-cell immunotherapy trials, and has one of the largest pipelines of open clinical trials aimed at treating pediatric blood and solid tumor cancers that do not respond to standard therapy by harnessing the immune system.

largest pipelines of open clinical trials

Seattle Children’s strongly believes there is an opportunity to combine the strengths of multiple hospital researchers into this collaborative effort to expand the reach of pediatric immunotherapy cancer trials. CureWorks will not only increase the number of immunotherapy trial sites around the globe, it will also aim to

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD